• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Carlsmed Inc.

    2/25/26 4:15:33 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care
    Get the next $CARL alert in real time by email
    S-8 1 carl-20260225.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 25, 2026

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE

    SECURITIES ACT OF 1933

     

    Carlsmed, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    83-1081863

    (State or other jurisdiction of

    incorporation or organization)

    (IRS Employer

    Identification Number)

     

     

    1800 Aston Ave, Suite 100

    Carlsbad, California

    92008

    (Address of principal executive offices)

    (Zip code)

    Carlsmed, Inc. 2025 Equity Incentive Plan

    Carlsmed, Inc. 2025 Employee Stock Purchase Plan

    (Full title of the plan)

    Michael Cordonnier

    Chairman, Chief Executive Officer, President and Co-Founder

    Carlsmed, Inc.

    1800 Aston Ave, Suite 100

    Carlsbad, California 92008

    (Name and address of agent for service)

    (760) 766-1923

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    H. Thomas Felix

    R. John Hensley

    James M. Krenn

    Morrison & Foerster LLP

    12531 High Bluff Drive, Suite 200

    San Diego, California 92130

    (858) 720-5100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

     

     


    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

     

    EXPLANATORY NOTE

    This Registration Statement is filed by Carlsmed, Inc. (the “Registrant”) for the purpose of registering (i) 1,333,212 additional shares of the Registrant’s common stock, par value $0.00001 per share (“Common Stock”) available for issuance under the Carlsmed, Inc. 2025 Equity Incentive Plan (the “Plan”) pursuant to the “evergreen” provision of the Plan and (ii) 266,642 additional shares of Common Stock available for sale and issuance under the Carlsmed, Inc. 2025 Employee Stock Purchase Plan (the “ESPP”) pursuant to the “evergreen” provision of the ESPP. The “evergreen” provisions of the Plan and the ESPP provide that the maximum amount of shares of Common Stock authorized under the Plan and the ESPP will be increased on January 1 of each year by a number equal to five percent (5%) and one percent (1%), respectively, of the total number of shares of Common Stock outstanding on December 31st of the immediately preceding calendar year. In accordance with General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements on Form S-8 (File No. 333-288915) filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on July 24, 2025 relating to the Plan and the ESPP.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Not required to be filed with this Registration Statement.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit No.

    Description

     

     

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated July 24, 2025 (File No. 001-42756)).

     

     

     

    4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K dated July 24, 2025 (File No. 001-42756)).

     

     

     

    4.3#

     

    2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q filed on August 28, 2025 (File No. 001-42756)).

     

     

     

    4.4#

     

     

    2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Quarterly Report on Form 10-Q filed on August 28, 2025 (File No. 001-42756).

     

     

     

    4.5#

     

     

    Form of Option Award Agreement under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-288339)).

     

     

    4.6#

     

     

    Form of RSU Award Agreement under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-288339)).

     

     

     

    4.7#

     

    Form of PSU Award Agreement under the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Registrant's Annual Report on Form 10-K filed on February 25, 2026 (File No. 001-42756).

     

     

     

    5.1*

    Opinion of Morrison & Foerster LLP.

     

     

    23.1*

    Consent of Independent Registered Accounting Firm.

     

     

    23.2*

    Consent of Morrison & Foerster LLP (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on the signature page to this Registration Statement).

     

     

     

    107*

     

    Filing Fee Table.

     

     

    * Filed herewith.

    # Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State California, on the 25th day of February, 2026.

     

     

    Carlsmed, Inc.

     

     

     

     

    By:

    /s/ Michael Cordonnier

     

     

    Michael Cordonnier

     

     

    Chief Executive Officer, President and Co-Founder

     

     

    Chairman of the Board of Directors

     

    SIGNATURES AND POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael Cordonnier and Leonard Greenstein and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to the Registration Statement), and to file the same, with all exhibits thereto, and any other documents in connection therewith, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

    Date

     

     

     

    /s/ Michael Cordonnier

    Michael Cordonnier

    Chairman, Chief Executive Officer, President and Co-Founder

    (Principal Executive Officer)

    February 25, 2026

     

     

     

    /s/ Leonard Greenstein

    Leonard Greenstein

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    February 25, 2026

     

     

     

    /s/ Kevin O‘Boyle

    Kevin O‘Boyle

    Director

    February 25, 2026

     

     

     

    /s/ Niall Casey

    Niall Casey

    Director

    February 25, 2026

     

     

     

    /s/ Robert Mittendorff

    Robert Mittendorff

    Director

    February 25, 2026

     

     

     

    /s/ Jonathan Root

    Jonathan Root

    Director

    February 25, 2026

     

     

     

    /s/ Kevin Sidow

    Kevin Sidow

    Director

    February 25, 2026

     

     

     

    /s/ Philip Young

    Philip Young

    Director

    February 25, 2026

     


    Get the next $CARL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARL

    DatePrice TargetRatingAnalyst
    8/18/2025$19.00Buy
    Goldman
    8/18/2025$18.00Overweight
    Piper Sandler
    8/18/2025$18.00Buy
    Truist
    8/18/2025$21.00Buy
    BTIG Research
    8/18/2025$16.00Buy
    BofA Securities
    More analyst ratings

    $CARL
    SEC Filings

    View All

    SEC Form S-8 filed by Carlsmed Inc.

    S-8 - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:15:33 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Carlsmed Inc.

    10-K - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:09:56 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CARLSMED, INC. (0001794546) (Filer)

    2/25/26 4:05:28 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Carlsmed with a new price target

    Goldman initiated coverage of Carlsmed with a rating of Buy and set a new price target of $19.00

    8/18/25 9:56:23 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Carlsmed with a new price target

    Piper Sandler initiated coverage of Carlsmed with a rating of Overweight and set a new price target of $18.00

    8/18/25 9:55:24 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Truist initiated coverage on Carlsmed with a new price target

    Truist initiated coverage of Carlsmed with a rating of Buy and set a new price target of $18.00

    8/18/25 8:55:58 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CARL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CARL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference

    CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET. A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/RczDxtnmshQKpi2ivHQcH3 About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and bey

    4/1/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.  "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o

    2/25/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference

    CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   A live webcast will be available to registered participants. Following the presentation, the webcast replay will be available at https://event.summitcast.com/view/d69xRqMspwymhwGUDdQoes/JC9qqvWhWggYawxGnDNtmz About Carlsmed, Inc. Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healt

    2/23/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    CEO, President Cordonnier Michael exercised 391,686 shares at a strike of $0.68 and sold $2,629,889 worth of shares (197,855 units at $13.29), increasing direct ownership by 14% to 1,550,477 units (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    3/4/26 4:05:03 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Durall William Scott was granted 44,977 shares (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    1/30/26 5:24:27 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Chief IP Officer Casey Niall was granted 44,977 shares, increasing direct ownership by 5% to 982,562 units (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    1/30/26 5:23:14 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Large owner B Capital Group Management, L.P. converted options into 6,988,430 shares and bought $19,999,995 worth of shares (1,333,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:51:14 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Director Sidow Kevin was granted 17,333 shares, converted options into 28,900 shares and bought $199,995 worth of shares (13,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:32:18 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Director Mittendorff Robert Ii converted options into 6,988,430 shares and bought $19,999,995 worth of shares (1,333,333 units at $15.00) (SEC Form 4)

    4 - CARLSMED, INC. (0001794546) (Issuer)

    7/24/25 8:31:12 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Leadership Updates

    Live Leadership Updates

    View All

    Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary

    CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics, Inc. and Progress Software Corporation. "We are pleased to welcome Jennifer to the Carlsmed

    9/29/25 9:00:50 AM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    $CARL
    Financials

    Live finance-specific insights

    View All

    Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY  CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.  "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion to 76.5%, and reduction of our lead times to within six business days. These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture o

    2/25/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call. Event Date: Wednesday, February 25, 2026Time: 1:30 PM Pacific Time Participant Registration: https://register-conf.media-server.com/register/BIb45

    2/11/26 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care

    Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance

    Third quarter revenue of $13.1 million, representing 98% growth YoY  Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.  "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and

    11/6/25 4:01:00 PM ET
    $CARL
    Medical/Dental Instruments
    Health Care